AIDS DNA vaccine that prevents SIVmac239 virus infection in monkeys
US6818442B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 6, 2000 |
| Grant date | Nov 16, 2004 |
| Priority date | — |
| Expiry date | Feb 1, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a plasmid carrying simian immunodeficiency virus (SIV)-derived genes. Particularly, the present invention relates to the plasmid pSIV/GE which carrys gag, protease, env and rev gene, all derived from SIV, but not tat and nef gene and the plasmid pSIV/pol which carrys SIV-derived pol gene; the plasmid pHIV/GE and pHIV/pol that are substituted the SIV-derived genes in the plasmid pSIV/GE and pSIV/pol by human immunodeficiency virus (HIV)-derived corresponding genes; DNA vaccine containing the plasmid pSIV/GE and pSIV/pol; and DNA vaccine containing the plasmid pHIV/GE and pHIV/pol. The present invention offers AIDS DNA vaccines which successfully exert perfect medicinal efficacy on primates, giving a measure of success in developing effective AIDS DNA vaccines applicable to humans. The plasmid of the present invention can be effectively used for not only AIDS prevention by AIDS infection but also therapeutic agent for AIDS.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.